Genome editing for the treatment of tumorigenic viral infections and virus-related carcinomas

Front Med. 2018 Oct;12(5):497-508. doi: 10.1007/s11684-017-0572-1. Epub 2018 Apr 12.

Abstract

Viral infections cause at least 10%-15% of all human carcinomas. Over the last century, the elucidation of viral oncogenic roles in many cancer types has provided fundamental knowledge on carcinogenetic mechanisms and established a basis for the early intervention of virus-related cancers. Meanwhile, rapidly evolving genome-editing techniques targeting viral DNA/RNA have emerged as novel therapeutic strategies for treating virus-related carcinogenesis and have begun showing promising results. This review discusses the recent advances of genome-editing tools for treating tumorigenic viruses and their corresponding cancers, the challenges that must be overcome before clinically applying such genome-editing technologies, and more importantly, the potential solutions to these challenges.

Keywords: delivery method; genome-editing tools; off-target effect; tumorigenic virus; virus-related carcinoma.

Publication types

  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • CRISPR-Cas Systems*
  • Carcinoma / genetics
  • Carcinoma / therapy*
  • Carcinoma / virology*
  • Gene Editing
  • Genetic Predisposition to Disease
  • Genetic Therapy / methods*
  • Humans
  • Tumor Virus Infections / complications*

Substances

  • Antiviral Agents